# Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

> **NCT03954704** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 22 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Dalutrafusp alfa
- **DRUG:** mFOLFOX6 Regimen
- **DRUG:** Dalutrafusp alfa

## Key facts

- **NCT ID:** NCT03954704
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-03
- **Primary completion:** 2020-10-27
- **Final completion:** 2021-04-15
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The decision to discontinue the study was made based on the totality of the clinical, pharmacokinetic, and pharmacodynamic findings. No safety concerns were observed.
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03954704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03954704, "Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03954704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*